Recent developments indicate that telehealth prescribers may face intensified scrutiny, particularly those linked to companies the FDA has warned regarding the marketing of compounded weight loss drugs.
In a related matter, Lilly is reportedly taking a stand against compounding practices that it views as problematic, signifying a push to regulate these practices more strictly.
Additionally, CVS has reinstated Lilly's obesity drug to its formularies, marking a significant shift in the availability of this treatment option.
Updates
Update at 13:26 UTC on 2026-05-28
STAT reported In this morning's Pharmalittle roundup, we're reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more.
Sources: STAT